BRCA2 and breast neoplasm: Clinical trials are currently underway to determine the efficacy of PARP inhibitors in treating BRCA deficient breast tumors, which may open new avenues for less toxic therapies that target particular DNA repair pathways in BRCA1 and BRCA2 mutation carriers [37].